Takeda Pharmaceutical (TAK) Receivables - Net (2018 - 2025)
Takeda Pharmaceutical (TAK) has 8 years of Receivables - Net data on record, last reported at $4.3 billion in Q1 2025.
- For Q1 2025, Receivables - Net fell 11.95% year-over-year to $4.3 billion; the TTM value through Mar 2025 reached $4.3 billion, down 11.95%, while the annual FY2025 figure was $4.3 billion, 14.19% down from the prior year.
- Receivables - Net reached $4.3 billion in Q1 2025 per TAK's latest filing, down from $4.8 billion in the prior quarter.
- Across five years, Receivables - Net topped out at $6.7 billion in Q1 2021 and bottomed at -$55.6 million in Q1 2023.
- Average Receivables - Net over 5 years is $3.1 billion, with a median of $4.3 billion recorded in 2025.
- Peak YoY movement for Receivables - Net: plummeted 100.77% in 2022, then soared 8820.35% in 2024.
- A 5-year view of Receivables - Net shows it stood at $6.7 billion in 2021, then tumbled by 100.77% to -$51.4 million in 2022, then dropped by 8.09% to -$55.6 million in 2023, then skyrocketed by 8820.35% to $4.8 billion in 2024, then dropped by 11.95% to $4.3 billion in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $4.3 billion in Q1 2025, $4.8 billion in Q1 2024, and -$55.6 million in Q1 2023.